Pfizer Receives “Approvable” Letter For MRSA Antibiotic Dalbavancin

Broad range of issues - from trial design to manufacturing - must be addressed before firm can add product to its antibiotic portfolio.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet